CONGRESS | #ASCO21 | @BerdejaJesus presents the updated results of the MonumenTAL-1 trial, evaluating talquetamab, a novel bsAb targeting GPRC5D/CD3, in heavily pretreated patients with RRMM #mmsm @SarahCannonDocs pic.twitter.com/fFyXdM3tMq
— Multiple Myeloma Hub (@MM_Hub) June 8, 2021